Targeting Sclerostin and Dkk1 at Optimized Proportions of Low-Dose Antibody Achieves Similar Skeletal Benefits to Higher-Dose Sclerostin Targeting in the Mature Adult and Aged Skeleton

Age-associated low bone mass disease is a growing problem in the US. Development of osteoanabolic therapies for treating skeletal fragility has lagged behind anti-catabolic therapies, but several bone-building molecules are clinically available. We reported previously that antibody-based neutralizat...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Roy B., Hoggatt, April M., Horan, Daniel J., Rogers, Emily Z., Hong, Jung Min, Robling, Alexander G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JKL International LLC 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662273/
https://www.ncbi.nlm.nih.gov/pubmed/36465166
http://dx.doi.org/10.14336/AD.2022.0315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662273/
https://www.ncbi.nlm.nih.gov/pubmed/36465166
http://dx.doi.org/10.14336/AD.2022.0315

Ejemplares similares